-
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
06 May 2024 12:00 GMT
… developing proprietary, innovative and differentiated therapies for the treatment … of its Investigational New Drug application (“IND”) by … to-severe adult-onset rheumatoid arthritis, with top line … results from clinical trials of its product candidates …
-
Lower Antioxidant Intake Linked to Endometriosis-Related Rheumatoid Arthritis Risk in Women of Childbearing Age
03 May 2024 23:45 GMT
… risk of endometriosis (EM)-related rheumatoid arthritis (RA) was observed among women … indicates an elevated risk of developing RA in female patients with … baseline characteristics, comorbidities, family history, treatments, and dietary intake of eligible …
-
The unique and complex origins of rheumatoid arthritis
03 May 2024 12:25 GMT
The study also revealed that these ACPAs are extensively modified with sugar molecules, known as Fab glycans. Intriguingly, some antibodies had multiple sugar molecules attached. This is much more then researchers normally observe in antibody profiles. …
-
SecondWave’s ultrasound therapy improves rheumatoid arthritis in pilot study
02 May 2024 19:18 GMT
… events.
Patients received splenic ultrasound treatment five times daily for two … clinical trial, most study participants started with moderate or high rheumatoid arthritis disease … 2021, the US Food and Drug Administration (FDA) stated it was receiving …
-
Dementia risk lower in patients with rheumatoid arthritis treated with biologic DMARDs
02 May 2024 13:40 GMT
… trials assessing their “neuroprotective potentials.”
Dementia risk decreases among patients with rheumatoid arthritis … to attenuate the development of dementia, and antirheumatic drugs are, therefore, … assess the impact of DMARD treatment in RA on the risk …
-
Researchers unveil unique autoantibody profiles in rheumatoid arthritis patients
02 May 2024 11:58 GMT
… that are involved in the development of the disease. Researchers at … .
Different approaches for treatment
Current efforts to develop treatments for RA are mainly … of human autoantibody repertoires in rheumatoid arthritis. Nature Communications. doi.org…
-
FDA Roundup: Humira Biosimilar, WHIM Syndrome Treatment
03 May 2024 21:06 GMT
… of moderate-to-severe rheumatoid arthritis in adults; moderate- … controlled, multicenter, randomized trial to determine if tisotumab … Treatment of Atopic Dermatitis
The FDA accepted a supplemental new drug … ) phase 3 development program. The FDA has assigned a …
-
Amgen Pushes Obesity Drug MariTide Forward, Reports 22% Q1 Revenue Growth
03 May 2024 16:19 GMT
… trial later this year, testing MariTide for the treatment … obesity treatments.
Meanwhile, as Amgen accelerates the development of … an early-stage obesity pill.
During Thursday’s … (etanercept), indicated for rheumatoid arthritis and plaque psoriasis, which …
-
Long-Term Outcomes of Targeted Treatment in Early RA: Insights from BeSt and IMPROVED Studies
03 May 2024 14:13 GMT
… term clinical outcomes in early rheumatoid arthritis that was treated-to- … used BeSt and IMPROVED trials to determine the disease outcome … 10 years, where the treatment target was low disease activity … .4). In an IMPROVED trial, 610 patients with early RA …
-
Amgen 'encouraged' by weight-loss drug interim data, shares jump
03 May 2024 13:34 GMT
… the Phase 2 MariTide trial late this year. Amgen … we will not pursue further development."
The company had … million for cholesterol drug Repatha. Sales of rheumatoid arthritis drug Enbrel fell 2 …
Excluding Horizon's medications, Amgen said year-over- …